The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index; 24 of the 32 sources its claims cite were checked for support.
NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy
Open accessAbstract
eIF4A-targeted translational inhibitors, such as silvestrol and its analogues, have emerged as strong anticancer therapies. Here, we tested the efficacy of eIF4A inhibition across a large and diverse panel of cancer cell lines and found B cell lymphomas to be the most sensitive group. Moreover, we performed a genetic screen and identified NRF2 activation as a major mechanism of resistance to silvestrol and related eIF4A inhibitors. Mechanistically, NRF2 activation broadly increases protein synthesis, and this effect is more pronounced on specific mRNAs that require eIF4A for translation. Finally, blocking NRF2 function by preventing its deglycation restores silvestrol sensitivity in cells that harbor NRF2 activation.
Overview
CoChat Summary
## TL;DR
This paper shows that the eIF4A inhibitor CR-1-31 B is highly active against aggressive B cell lymphomas, with nanomolar potency and in vivo tumor growth inhibition. It also identifies NRF2 activation as a major resistance mechanism and shows that FN3K loss can restore sensitivity.
## Key findings
- In a DepMap-based screen of 183 cancer cell lines, lymphoma cells were the most sensitive to CR-1-31 B; in aggressive DLBCL lines, IC50 values ranged from <1 nM (suDHL-4) to 5 nM (SuDHL-10, Ly8, and TMD8).
- In vivo, CR-1-31 B treatment impaired growth of suDHL-6 xenografts (n = 10, p < 0.05) and a patient-derived MYC+/BCL2+ DLBCL xenograft (n = 5, p < 0.05), with no weight loss or mortality reported.
- A genome-wide CRISPR/Cas9 screen in FL5-12 cells identified KEAP1, CUL3, and CAND1 as resistance-linked hits; loss of these NRF2 repressors reduced silvestrol sensitivity, and NRF2 knockdown restored wild-type sensitivity.
- NRF2 activation increased global protein synthesis and specifically boosted translation of eIF4A-dependent mRNAs such as MYC and BCL2; in Keap1-edited FL5-12 cells, the eIF4A-dependent reporter increased 1.5-fold (`n = 3, p < 0.05`), and silvestrol’s suppression of MYC/BCL2 was largely blunted.
- FN3K inactivation reversed NRF2-driven resistance: in Fn3k-proficient cells, DLS induced about a 6-fold increase in Nqo1, which dropped by about 50% with Fn3k editing; Fn3k silencing also largely reversed silvestrol resistance in Keap1-edited cells.
## Methods
- The study combined a large-scale drug sensitivity screen (183 cell lines), in vitro viability assays, AHA metabolic labeling, luciferase reporter assays, qPCR/immunoblotting, CRISPR/Cas9 genetic editing and genome-wide screen, and in vivo xenograft models.
- The CRISPR screen used FL5-12 cells with doxycycline-inducible Cas9 and a genome-wide library of about 90,000 sgRNAs targeting ~19,000 genes, followed by three cycles of silvestrol (10 nM) selection versus DMSO control.
- The paper also analyzed DepMap data, used a 34-patient DLBCL tissue microarray for IHC, and assessed significance with DESeq/DESeq2 and Welch-corrected t tests.
## Limitations
- The paper states that NRF2-activating lesions are rare in lymphoma, although frequent in advanced solid tumors; this limits how broadly the resistance mechanism may explain lymphoma response specifically.
- The text makes evident that several key conclusions come from cell lines and xenografts, with only a small patient tissue cohort (n = 34) for IHC; this is an evident limitation because clinical validation is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
13 Valid · 1 Not valid · 2 Not checked · 32 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“NRF2-activating mutations are rare in untreated lymphomas; however, they have been associated with chemo- and radiation resistance in lymphoma [37,38], leukemia [39], and in solid tumors [40].”
§ NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy > 3. Discussion
What the sources say
- Could not verifycites [37] Intlekofer, 2018, Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay, Blood Cancer J. sourceExperimental — accuracy not yet measured
The citation is attached to the lymphoma portion of the resistance claim. The Results and Discussion passages in our copy discuss other genomic alterations in diffuse large B-cell lymphoma, but do not address NRF2-activating mutations or their association with chemotherapy or radiation resistance; searches for NRF2, NFE2L2, KEAP1, and treatment resistance found no relevant passage. The leukemia and solid-tumor portions are attributed to other citations. (LLM, conf=0.74)
- Partly supportedcites [38] Kari, 2019, Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP, J. Clin. Pathol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links high Nrf2 levels to chemoresistance and reduced radiotherapy sensitivity, and reports Nrf-related chemoresistance in multiple myeloma. It does not attribute those effects to NRF2-activating mutations or establish radiation resistance specifically in lymphoma. The citing sentence assigns the leukemia and solid-tumor portions to other references. (LLM, conf=0.85)
- Disputedcites [39] Rushworth, 2012, The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance, Blood sourceExperimental — accuracy not yet measured
The cited sentence attributes to this paper the association of NRF2-activating mutations with chemo- and radiation resistance in leukemia, but our copy's central finding runs the other way: the Abstract states AML nuclear Nrf2 elevation arises 'from an imbalance between mRNA expression levels of Nrf2 and its inhibitor Keap1 but not through their somatic mutation,' and the Results section 'High Nrf2 protein in human AML cells is because of elevated Nrf2 RNA levels' reports no mutations in Nrf2/Keap1 in 21 of 22 primary AML samples. The Discussion (opening paragraph) makes it explicit: 'in human AML high Nrf2 is not linked to mutations within Keap1 or in Nrf2 but is in fact the result of an aberrant up-regulation of Nrf2 by NF-B.' The paper does support Nrf2-dependent chemo-resistance in AML (Knockdown of Nrf2 enhances chemotherapy-induced apoptosis; Figures 5-6, daunorubicin/cytarabine and bortezomib), but via NF-κB-driven transcription, not activating mutations, and radiation resistance is not addressed anywhere in our copy; the mutation-driven mechanism it does discuss is credited to other works in solid tumours (refs 29, Ohta 2008 lung cancer; 30, Kim 2011 oesophageal/skin squamous carcinoma). (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [40] Helena, 2018, Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance, Clin. Cancer Res. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links KEAP1 loss and increased NRF2 expression to possible resistance to RTK/MAPK pathway inhibitors in non-small-cell lung cancer. Citation [40] is attached to the solid-tumor portion of the citing sentence, but the source does not establish resistance to chemotherapy or radiation, or address NRF2-activating mutations specifically. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Indeed, NRF2 is known to augment global protein production by reducing key translation factors such as eEF2 [15].”
§ NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy > 3. Discussion
What the sources say
- Supportedcites [15] Chio, 2016, NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer, Cell source
The Introduction says NRF2 promotes global protein synthesis by maintaining reduced cysteine residues in proteins that regulate translation. The Results section on impeded translation identifies eEF2 as a possible redox switch: an oxidation-mimicking eEF2 variant decreased nascent protein synthesis. Here, “reducing” is supported as a change in redox state, not a decrease in the amount of eEF2. (LLM, conf=0.85)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with our previous findings [21], we see that silvestrol blocks the translation of the MYC and BCL2 mRNAs, without affecting the GAPDH housekeeping gene, across several lymphoma lines (SuDHL-4, SuDHL-6, SuDHL-10, Ly8) (Figure 1D).”
§ NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy > 2. Results > 2.1. CR-1-31 B Kills Aggressive Lymphoma Cells at Nanomolar Concentrations
What the sources say
- Partly supportedcites [21] Wolfe, 2014, RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer, Nat. Cell Biol. sourceExperimental — accuracy not yet measured
The Results section, “What transcripts are affected by Silvestrol?” (page unavailable), reports effects on MYC and says housekeeping genes showed no change in ribosome-footprint profiles; the Discussion also identifies BCL2 as a silvestrol-sensitive oncogene. Our copy does not establish unchanged GAPDH translation specifically. The named lymphoma lines are presented as the citing authors’ new observation, not a finding attributed to this source. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It is especially active against aggressive MYC+/BCL2+ B cell lymphomas and this likely reflects the eIF4A-dependent translation of both MYC and BCL2.”
§ NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy > Abstract
What the sources say
- Partly supportedcites [21] Wolfe, 2014, RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer, Nat. Cell Biol. sourceExperimental — accuracy not yet measured
The Discussion (‘A selective mechanism of translational control’; page not provided) identifies MYC and BCL2 as eIF4A-sensitive oncogenes. The Results (‘eIF4A is an oncogene in T-ALL’; page not provided) report activity of CR-31-B against T-ALL, not aggressive MYC+/BCL2+ B-cell lymphomas. Thus the proposed mechanism is plausible from this paper, but the claimed sensitivity of that lymphoma subtype is not established by it. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The eIF4A helicase is uniquely required for the translation of mRNAs with long and highly structured 5′ UTRs, including those with guanine tetrad sequences that are thought to fold into G-quadruplex (GQ) structures [21].”
§ NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy > 1. Introduction
What the sources say
- Partly supportedcites [21] Wolfe, 2014, RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer, Nat. Cell Biol. sourceExperimental — accuracy not yet measured
The Discussion (page not supplied) links eIF4A-dependent translation to a subset of transcripts with long 5′ UTRs and G-quadruplex motifs. The Results (page not supplied) find eIF4A limiting for translation of a G-quadruplex reporter, but also note that other helicases may resolve G-quadruplexes. The paper does not establish that eIF4A is uniquely required for all mRNAs with long, highly structured 5′ UTRs. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 48 claims and to verify the 3 references still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 13
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, a genome-wide CRISPR/Cas9 screen revealed that eIF4A2 inactivation confers resistance to silvestrol, highlighting the role of eIF4A2 in modulating response to eIF4A-targeted treatments (32).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A synthetic eIF4A inhibitor, CR-1-31B, has shown potent activity against many cancer cell lines and promising efficacy in several mouse models (15, 17, 20, 21, 32, 33).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“MDR1/P-glycoprotein (Pgp) overexpression and NRF2 activation have also been implicated in resistance to eIF4A inhibitors (32, 42).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, a genome-wide CRISPR/Cas9 screen revealed that eIF4A2 inactivation confers resistance to silvestrol, highlighting the role of eIF4A2 in modulating response to eIF4A-targeted treatments (32).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [32]
Citations
Cites
Genome-Wide Analysis in Vivo of Translation with Nucleotide Resolution Using Ribosome Profiling
Ingolia, N. T., Ghaemmaghami, S., Newman, J. R. S., & Weissman, J. S. (2009) · Science · doi:10.1126/science.1168978 · Cited by 3,853 · cited 1×
“The newer methods based on ribosome profiling and RNA sequencing provide more accurate and statistically sound data [25].”
MethodNRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 1×
“For example, NRF2 steers glucose to anabolic cancer metabolism and prevents oxidation of multiple translational factors to augment protein output [15,16].”
BackgroundThe emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway
Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,086
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067
Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2800 · Cited by 1,064 · cited 1×
“Briefly, we engineered FL5‐12 cells, a silvestrol‐sensitive immortalized murine B cell line (IC50, ~5 nM), to express Cas9 in a doxycycline dependent manner (FL5‐ 12‐TRE‐Cas9‐GFP) and transduced them with a genome‐wide CRISPR library (~90,000 sgRNAs targeting ~19,000 genes) [28].”
MethodHediger, M. A., Romero, M. F., Peng, J.-B., Rolfs, A., Takanaga, H., & Bruford, E. A. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1192-y · Cited by 985 · cited 1×
“Additionally, we see three sgRNAs targeting the xenobiotic uptake and secretion factor Slc22 a23 indicating a role for it in silvestrol import [30].”
BackgroundNrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839
Translational control in cancer
Silvera, D., Formenti, S. C., & Schneider, R. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2824 · Cited by 821
Cited by
DEAD-Box RNA Helicases in Cell Cycle Control and Clinical Therapy
Zhang, L., & Li, X. (2021) · Cells · doi:10.3390/cells10061540 · Cited by 53
“The Therapeutic Potential of RNA Helicase Inhibitors in the Treatment of Various Disorders As described above, different inhibitors of RNA helicases have been developed, which may potentially be used in disease treatment [47,123,124].”
BackgroundIslam, S. S., Qassem, K., Islam, S., Parag, R. R., Rahman, M. Z., Farhat, W. A., Yeger, H., Aboussekhra, A., Karakas, B., & Noman, A. S. M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05126-8 · Cited by 44
“Furthermore, loss of Keap1 and Nrf2 activation has previously been reported to confer resistance to chemotherapy [35, 36].”
BackgroundThe role of eIF4F-driven mRNA translation in regulating the tumour microenvironment
Bartish, M., Abraham, M. J., Gonçalves, C., Larsson, O. S., Rolny, C., & Rincon, S. V. D. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00567-5 · Cited by 42
Zhang, H., Xia, P., Yang, Z., Liu, J., Zhu, Y., Huang, Z., Zhang, Z., & Yuan, Y. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1443 · Cited by 32
“24,25 HCC data from The Cancer Genome Atlas (TCGA) suggest that CAND1 mRNA is upregulated and an indicator of an unfavourable prognosis.”
Novel eIF4A1 inhibitors with anti‐tumor activity in lymphoma
Kayastha, F. B., Herrington, N. B., Kapadia, B. B., Roychowdhury, A., Nanaji, N. M., Kellogg, G. E., & Gartenhaus, R. B. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00534-0 · Cited by 25
Metadata
- Authors
- Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., & Wendel, H.-G.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Department of Antitumor Assessment Core and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Corresponding author
- Sanghvi, Viraj R.
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-02-05
- Volume
- 13
- Issue
- 4
- Pages
- 639
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7915661
- OpenAlex
- W3128657146
- Semantic Scholar
- 0ab5ece9dfe0a2ceb663c06e1d49d5231444e309
- Cited by
- 27
- References
- 43
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 7 · 2023: 6 · 2022: 5 · 2021: 3
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- National Cancer Institute (P30CA008748, P50CA217694, P30CA240139)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- Nrf2, silvestrol, drug resistance, B-cell lymphoma, Keap1, CUL3, CAND1, protein glycation, translational regulation, CRISPR-Cas9 screen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. https://app.cochat.ai/papers/10.3390/cancers13040639
- The paper
- Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., & Wendel, H.-G. (2021). NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. Cancers. https://doi.org/10.3390/cancers13040639
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.